A Randomized Clinical Trial Comparing Nelfinavir and Ritonavir in Patients with Advanced HIV Disease (CPCRA 042/CTN 102)

Perez, George; MacArthur, Rodger D.; Walmsley, Sharon; Baxter, John; Mullin, Chris; Neaton, James D.

doi:10.1310/n11f-nk93-mumr-a1vv

Cited by 10 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with VA was associated with increased expression of p21, downregulation of cyclin A, and induction of cell-cycle arrest in G1 phase in PTC-derived cells (Catalano et al 2005). In FTC-and PTC-derived cell lines, treatment with VA was associated with downregulation of anti-apoptotic genes (BCL2, BCL-xl), upregulation of a pro-apoptotic gene (Perez et al 2004), and induction of apoptosis (Shen et al 2005). VA also decreased invasiveness of FTC and PTC-derived TC cells through inhibition of MMP-2 and MMP-9 and sensitized ATC-derived cells to treatment with doxorubicin (Kim et al 2009, Mitmaker et al 2011.…”

Section: Valproic Acidmentioning

confidence: 94%

Repositioning therapy for thyroid cancer: new insights on established medications

Kushchayeva¹,

Jensen²,

Burman³

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

Repositioning of established non-cancer pharmacotherapeutic agents with well-known activity and side-effect profiles is a promising avenue for the development of new treatment modalities for multiple cancer types. We have analyzed some of the medications with mechanism of action that may have relevance to thyroid cancer (TC). Experimental in vitro and in vivo evidences, as well as results of clinical studies, have indicated that molecular targets for medications currently available for the treatment of mood disorders, sexually transmitted diseases, metabolic disorders, and diabetes may be active and relevant in TC. For instance, the derivatives of cannabis and an anti-diabetic agent, metformin, both are able to inhibit ERK, which is commonly activated in TC cells. We present here several examples of well-known medications that have the potential to become new therapeutics for patients with TC. Repositioning of established medications for the treatment of TC could broaden the scope of current therapeutic strategies. These diverse treatment choices could allow physicians to provide an individualized approach to optimize treatment for patients with TC.

show abstract

Section: Valproic Acidmentioning

confidence: 94%

Repositioning therapy for thyroid cancer: new insights on established medications

Kushchayeva¹,

Jensen²,

Burman³

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…The surveys were designed by selecting questions from forms used in the Agency for Healthcare Research and Quality, and Research and Development co-sponsored HIV Cost and Services Utilization Study, 7 and a National Institutes of Health-sponsored study comparing nelfinavir and ritonavir in HIV patients. 8 Minor modifications in wording were made due to the clinical nature of PD compared with HIV (eg, the recording of Other Health Professional Visits, including physical, occupational, and speech therapists).…”

Section: Study Participants and Methodsmentioning

confidence: 99%

Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: The FS-TOO resource utilization substudy

Mauldin

Guimarães

Albin

et al. 2008

Clinical Therapeutics

View full text Add to dashboard Cite

Objective The aim of this substudy was to determine the agreement between 2 approaches for measuring health care resource utilization (eg, number of hospital visits, number of primary care physician visits) in trial participants with Parkinson’s disease (PD). Methods A substudy of the 1-year multicenter futility trial of GPI-1485 and coenzyme Q10 (FS-TOO) was performed to assess health care resource utilization agreement by measuring participant utilization recall after 12 months versus measuring participant utilization recall at regular 3-month intervals. Trial participants were selected from patients in the National Institutes of Health-sponsored FS-TOO multicenter study. Persons aged ≥30 years with confirmed PD diagnosis within the previous 5 years were eligible for inclusion in the substudy. Participants were also required to have at least 2 of 3 cardinal manifestations of PD (tremor, rigidity, and bradykinesia). Participants were excluded from the study if they had presence of atypical Parkinson’s syndromes due to drugs, metabolic identified neurogenetic disorders, encephalitis, or other degenerative diseases. Agreement was determined using Lin’s concordance and Cohen’s kappa statistics. Results Between March and July of 2004, a total of 424 potential subjects were identified and evaluated for trial eligibility. Of these, 213 subjects (139 men, 74 women; mean [SD] age, 61.5 [10.3] years) met entry criteria and were included in the study. Trial participants were randomized equally to 1 of 3 groups. The 3 groups had similar baseline characteristics in terms of demographic data (age, race, sex, employment status, and annual income), total Unified Parkinson Disease Rating Scale (UPDRS) score, and UPDRS subscores. In this substudy, 141 participants had a true baseline visit, indicating a clinical baseline date, and 182 participants completed the Baseline Resource Utilization Form within 3 months of the true baseline visit. The comparison of concordance between the summed information over 3-month recalls and the 12-month recall from baseline was derived from these 182 participants. The level of agreement between the 2 approaches was high, ranging from 64.4% to 95.1%. Where disagreement was identified, the more frequent measurement approach (every 3 months) led to higher estimates, ranging from 20.4% to 77.4%. Conclusion The results of this trial indicate internal consistency with the self-reported measures of health care resource utilization, suggesting that these simple measures might provide reliable information about units of health care resource utilization in the context of clinical trials for PD.

show abstract

Governmental Support of Research

Vermund

Karim

2009

Clinical and Translational Science

View full text Add to dashboard Cite

A Randomized Clinical Trial Comparing Nelfinavir and Ritonavir in Patients with Advanced HIV Disease (CPCRA 042/CTN 102)

Abstract: There are moderate differences in efficacy and large differences in tolerability between a strategy of initial NFV or RTV in patients with advanced disease. Finding the right balance between potency and tolerability remains a challenge.

Cited by 10 publications

References 24 publications

Repositioning therapy for thyroid cancer: new insights on established medications

Repositioning therapy for thyroid cancer: new insights on established medications

Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: The FS-TOO resource utilization substudy

Governmental Support of Research

Contact Info

Product

Resources

About